Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clobetasol propionate
Drug ID BADD_D00490
Description Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Indications and Usage For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
Marketing Status Prescription; Discontinued
ATC Code D07AD01
DrugBank ID DB01013
KEGG ID D01272
MeSH ID D002990
PubChem ID 32798
TTD Drug ID D0H0YD
NDC Product Code 63629-8637; 63739-064; 43538-950; 71589-004; 0168-0301; 50742-304; 43538-951; 50383-269; 63629-8639; 50383-267; 68071-1599; 0378-8055; 71589-002; 63629-2395; 50383-978; 49452-2141; 51672-1258; 71589-003; 63629-2393; 50383-270; 50090-4146; 0781-7137; 70700-106; 70518-2068; 71085-007; 46439-8747; 45802-637; 45802-961; 72189-262; 0299-3848; 0378-8147; 62559-980; 40032-028; 0472-0400; 16714-992; 70752-153; 62332-547; 68071-4706; 76003-0325; 71589-007; 51672-1347; 52565-051; 0168-0163; 50090-2289; 43386-096; 51672-4193; 0299-3847; 0378-8167; 33342-321; 52128-158; 70710-1401; 51672-1371; 63629-2330; 0299-3849; 0472-0404; 68462-625; 59088-762; 68788-7768; 52565-082; 70700-109; 70771-1498; 68788-7212; 68040-713; 10337-163; 69238-1732; 42291-076; 63629-2332; 0168-0269; 40032-096; 0472-0403; 63629-2392; 68462-532; 51672-1293; 71428-005; 62991-1492; 63629-2331; 71205-151; 50090-5778; 51672-1297; 70771-1209; 66993-939; 51672-1350; 52565-094; 68180-956; 68462-530; 64958-0101; 62332-425; 0168-0293; 69238-1532; 45802-437; 68462-608; 22552-0006; 79572-008; 16714-730; 62332-486; 13668-603; 50383-266; 70518-1178; 50090-5264; 70771-1080; 0713-0656; 51927-2627; 60429-901; 45802-925; 50090-5488; 51672-1294; 49502-537; 60432-133; 62332-465; 0168-0162; 50090-4630; 70710-1456; 50090-3820; 72578-085; 13668-569; 43538-953; 16714-030; 43538-952; 68462-529; 51552-0605; 68180-536; 63629-2329; 10337-162; 42571-362; 69482-700; 50383-268; 42291-077; 0378-8182; 64980-441; 50090-4647; 50090-5079; 68462-480; 52565-055; 50090-2405; 68180-551; 0472-0402; 51672-1259; 0591-4039; 63646-500; 63629-8638; 16714-782; 50383-979; 63629-2394; 52565-039; 60429-902; 46439-8708; 68382-998; 43386-028; 68071-1600; 68788-7581; 62332-548; 70771-1442; 71589-006; 50090-0548
Synonyms Clobetasol | Clofenazon | Clobetasol Propionate | Clobetasol 17-Propionate | Clobetasol 17 Propionate | Clobex | Cormax | OLUX | Dermovate | Embeline | Embeline E | Temovate
Chemical Information
Molecular Formula C25H32ClFO5
CAS Registry Number 25122-46-7
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CCl
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adrenal insufficiency05.01.02.001; 14.11.01.0040.000930%
Adrenal suppression05.01.02.002; 14.11.01.0050.000797%Not Available
Alopecia23.02.02.0010.000266%
Application site atrophy08.02.01.037; 12.07.01.037--Not Available
Application site irritation08.02.01.003; 12.07.01.003--Not Available
Application site pain08.02.01.004; 12.07.01.004--Not Available
Application site pruritus08.02.01.005; 12.07.01.005; 23.03.12.004--Not Available
Application site reaction08.02.01.006; 12.07.01.006--Not Available
Arthralgia15.01.02.0010.000266%
Atrophy08.03.04.001--Not Available
Back pain15.03.04.0050.000399%
Blood cholesterol increased13.12.01.0020.000266%
Blood cortisol decreased13.10.09.0040.000532%Not Available
Blood triglycerides increased13.12.03.0010.000266%Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Cerebral atrophy17.11.01.0010.000532%Not Available
Crepitations08.01.03.006--Not Available
Cushing's syndrome05.01.01.001; 14.11.01.007; 19.07.03.002; 24.08.04.0010.002658%Not Available
Cushingoid05.01.01.002; 14.11.01.006; 19.07.03.001; 24.08.02.0040.000532%
Delusion19.10.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004--Not Available
Dermatitis infected11.01.12.011; 23.03.04.024--Not Available
Discomfort08.01.08.0030.000266%Not Available
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.0010.000266%Not Available
Dry skin23.03.03.001--
Erythema23.03.06.0010.000797%Not Available
Eye irritation06.04.05.003--Not Available
Folliculitis11.01.12.018; 23.09.04.007--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages